0.509

0.50% 0.0065

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $0.509, with a volume of 1.18M. It is up +0.50% in the last 24 hours and down -14.20% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$0.5025

Open:

$0.5108

24h Volume:

1.18M

Relative Volume:

0.67

Market Cap:

$112.68M

Revenue:

$8.95M

Net Income/Loss:

$-21.49M

P/E Ratio:

-3.9154

EPS:

-0.13

Net Cash Flow:

$-29.24M

1W Performance:

+0.00%

1M Performance:

-14.20%

6M Performance:

-45.82%

1Y Performance:

-53.67%

1-Day Range:

$0.5026

$0.5297

1-Week Range:

$0.481

$0.5367

52-Week Range:

$0.481

$1.61

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (670)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2024-11-07

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	0.505	112.68M	8.95M	-21.49M	-29.24M	-0.12
VRTX Vertex Pharmaceuticals Inc	405.80	103.76B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	714.72	78.27B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	620.22	36.92B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	233.43	29.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.94	27.55B	3.30B	-501.07M	1.03B	-2.1146

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Jan 01, 2025

State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jan 01, 2025

Dec 30, 2024

Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register

Dec 30, 2024

Dec 28, 2024

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1%Here's What Happened - MarketBeat

Dec 28, 2024

Dec 17, 2024

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround - Yahoo Finance

Dec 17, 2024

Dec 14, 2024

BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 - Marketscreener.com

Dec 14, 2024

Dec 13, 2024

HC Wainwright Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Dec 05, 2024

Stem cell therapy companies take different roads to reproducibility - BioCentury

Dec 05, 2024

Dec 04, 2024

Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com

Dec 04, 2024

Dec 03, 2024

Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio? - Yahoo Finance

Dec 03, 2024

Dec 01, 2024

Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio? - Insider Monkey

Dec 01, 2024

Nov 26, 2024

Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock - Investing.com

Nov 26, 2024

Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock By Investing.com - Investing.com Australia

Nov 26, 2024

Lineage Cell Therapeutics director buys $22,639 in common shares - Investing.com India

Nov 26, 2024

Nov 25, 2024

Lineage Cell Therapeutics director buys $22,639 in common shares By Investing.com - Investing.com Australia

Nov 25, 2024

Nov 23, 2024

Brian M. Culley Buys 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock - MarketBeat

Nov 23, 2024

Nov 21, 2024

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering - Business Wire

Nov 21, 2024

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Nov 21, 2024

Lineage Cell Therapeutics FY2024 EPS Boosted by Cantor Fitzgerald - MarketBeat

Nov 21, 2024

Lineage Cell Therapeutics secures $30 million in direct offering By Investing.com - Investing.com Australia

Nov 21, 2024

LCTX Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia

Nov 21, 2024

Nov 20, 2024

Lineage Cell price target lowered to $2 from $3 at D. Boral Capital - TipRanks

Nov 20, 2024

Lineage Cell Therapeutics tumbles after pricing $66M securities offering - MSN

Nov 20, 2024

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering - BioSpace

Nov 20, 2024

Lineage Cell Therapeutics secures $30 million in direct offering - Investing.com

Nov 20, 2024

Lineage Cell Therapeutics Launches $66M Direct Offering with Warrants for OpRegen Development | LCTX Stock News - StockTitan

Nov 20, 2024

Allogeneic Stem Cells Market Is Expected To Reach $2.0 Billion - openPR

Nov 20, 2024

Nov 19, 2024

D. Boral Capital Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy Recommendation - MSN

Nov 19, 2024

Nov 18, 2024

Boral Capital sets Buy rating for Lineage Cell stock - Investing.com

Nov 18, 2024

Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital - TipRanks

Nov 18, 2024

Nov 15, 2024